期刊文献+

Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication 被引量:7

Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication
下载PDF
导出
摘要 Helicobacter pylori(H.pylori)is one of the most common chronic bacterial infections in humans,affecting half of world’s population.Therapy for H.pylori infection has proven to be both effective and safe.The oneweek triple therapy including proton pump inhibitor,clarithromycin,and amoxicillin or metronidazole is still recommended as a first-line treatment to eradicate H.pylori infection in countries with low clarithromycin resistance.Generally,this therapy is well-tolerated,with only a few and usually minor side effects.However,rare but severe adverse effects such as pseudomembranous colitis have been reported,Clostridium difficile(C.difficile)infection being the main causative factor in all cases.We report the cases of two women who developed pseudomembranous colitis after a 1-wk triple therapy consisting of pantoprazole 20 mg bid,clarithromycin 500 mg bid,and amoxicillin 1 g bid to eradicate H.pylori infection.A limited colonoscopy showed typical appearance of pseudomembranous colitis,and the stool test for C.difficile toxins was positive.Rapid resolution of symptoms and negative C.difficile toxins were obtained in both patients with oral vancomycin.No relapse occurred during a four and eleven-month,respectively,follow up.These cases suggest that physicians should have a high index of suspicion for pseudomembranous colitis when evaluate patients with diarrhea following H.pylori eradication therapy. Helicobacter pylori (H. pylori) is one of the most common chronic bacterial infections in humans, affecting half of world’s population. Therapy for H. pylori infection has proven to be both effective and safe. The one-week triple therapy including proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole is still recommended as a first-line treatment to eradicate H. pylori infection in countries with low clarithromycin resistance. Generally, this therapy is well-tolerated, with only a few and usually minor side effects. However, rare but severe adverse effects such as pseudomembranous colitis have been reported, Clostridium difficile (C. difficile) infection being the main causative factor in all cases. We report the cases of two women who developed pseudomembranous colitis after a 1-wk triple therapy consisting of pantoprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1 g bid to eradicate H. pylori infection. A limited colonoscopy showed typical appearance of pseudomembranous colitis, and the stool test for C. difficile toxins was positive. Rapid resolution of symptoms and negative C. difficile toxins were obtained in both patients with oral vancomycin. No relapse occurred during a four and eleven-month, respectively, follow up. These cases suggest that physicians should have a high index of suspicion for pseudomembranous colitis when evaluate patients with diarrhea following H. pylori eradication therapy.
出处 《World Journal of Gastroenterology》 SCIE CAS 2013年第42期7476-7479,共4页 世界胃肠病学杂志(英文版)
关键词 HELICOBACTER PYLORI eradication Triple therapy CLOSTRIDIUM DIFFICILE PSEUDOMEMBRANOUS colitis VANCOMYCIN Helicobacter pylori eradication Triple therapy Clostridium difficile Pseudomembranous colitis Vancomycin
  • 相关文献

参考文献30

  • 1Abhishek Deshpande,Chaitanya Pant,Vinay Pasupuleti,David D.K. Rolston,Anil Jain,Narayan Deshpande,Priyaleela Thota,Thomas J. Sferra,Adrian V. Hernandez.Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis[J]. Clinical Gastroenterology and Hepatology . 2012 (3)
  • 2Caoilfhionn O?Donoghue,Lorraine Kyne.Update on Clostridium difficile infection[J]. Current Opinion in Gastroenterology . 2011 (1)
  • 3Archimandritis,Souyioultzis,Katsorida,Tzivras.Clostridium difficile colitis associated with a ‘triple’ regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori[J]. Journal of Internal Medicine . 2008 (3)
  • 4Farrah Ibrahim J. Al-Tureihi,Ali Hassoun,Gisele Wolf-Klein,Henry Isenberg.Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficile- associated disease in nursing home patients[J]. Journal of the American Medical Directors Association . 2005 (2)
  • 5RakeshRai,SundeepaRai.Pseudomembranous colitis requiring surgical intervention following triple therapy for helicobacter pylori eradication[J]. ANZ Journal of Surgery . 2003 (12)
  • 6A. Nawaz,I. Mohammed,K. Ahsan,A. Karakurum,C. Hadjiyane,C. Pellecchia.Clostridium difficile colitis associated with treatment of Helicobacter pylori infection[J]. The American Journal of Gastroenterology . 1998 (7)
  • 7Hunt RH,Xiao SD,Megraud F,Leon-Barua R,Bazzoli F,van der Merwe S,et al.Helicobacter pylori in developing countries.World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis . 2011
  • 8Schweigart U,Franck H,Schepp W,Lehn N,Becker K,Classen M.[Toxic megacolon after Helicobacter pylori eradication therapy]. Der Internist . 1997
  • 9Megraud Francis.Helicobacter pylori and antibiotic resistance. Gut . 2007
  • 10Graham David Y,Fischbach Lori.Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut . 2010

同被引文献23

引证文献7

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部